Mereo BioPharma Group plc (MREO) › Cash & EquivalentsMereo BioPharma Group plc (MREO) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2022-12-31: $68.18M2023-12-31: $57.42M2024-12-31: $69.80M2025-12-31: $40.99M$40.99M2022-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$40.99M-41.3%2026-03-19Balance as of period end2024-12-31$69.80M+21.6%2026-03-19Balance as of period end2023-12-31$57.42M-15.8%2025-03-26Balance as of period end2022-12-31$68.18M—2024-03-27Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)